LDS/Medical Tests/Cancer Antigen Profile

Cancer Antigen Profile

Cancer antigens are proteins found within the body and are associated with certain malignancies (cancers). The measurement of these antigens can, along with other diagnostic tests, aid in the diagnosis of cancer, monitor disease progression, diagnose recurrence of disease, and monitor therapy. Tests for cancer antigens are not sensitive enough to be used as conclusive diagnosis or screening tests and should be used in addition to standard diagnostic practices. Grouped as a panel of tests, multiple cancer antigens can give the most information and allow a physician to diagnose and tailor therapies for certain cancers.

Cancer antigen 19-9 (CA 19-9) was developed as a marker to monitor colon cancer. However, CA19-9 has been proven very sensitive for pancreatic cancer. Normal levels of CA 19-9 can be found in very early stages of the cancer. Conversely, elevated levels are seen with advanced pancreatic cancer. CA 19-9 may also be elevated in other cancers such as colorectal cancer, lung cancer, gallbladder cancer, and in conditions such as gallstones, pancreatitis, cystic fibrosis, and liver disease. Bile duct obstruction may also cause very elevated CA 19-9 levels, which fall when the blockage is cleared. The clinical management of pancreatic cancer is extremely difficult with most having metastasized by the time of diagnosis. Monitoring the progression of disease is critical in management of cancer. Serial monitoring of CA 19-9 levels is valuable as an adjunct to imaging and clinical assessment. CA 19-9 is neither sensitive nor specific enough to be considered useful as a tool for cancer screening because by the time symptoms develop that would prompt the test, the disease is usually at an advanced stage.

Cancer Antigen 72-4 (CA 72-4) may be increased in multiple cancer types including pancreas, stomach, gallbladder, biliary tract, colon, breast, ovary, cervix, and endometrium. The highest values for CA 72-4 are most closely related to gastrointestinal cancer and ovarian cancer. CA 72-4 can also be associated with non-cancerous disease such as rheumatic disease and ovary cysts. CA 72-4 is used in conjunction with CA 19-9 and CEA assays to diagnose and monitor gastrointestinal cancer patients. CA 72-4 can also be used to help identify the stage of gastrointestinal cancer, due to a good correlation with the CA 72-4 levels and the stage of the cancer. CA 72-4 can be used as a monitoring assay for patients with ovarian cancer. This is most appropriate for those patients that have negative results for CA 125 (which is typically used to monitor ovarian cancer).

Cancer Antigen 27-29 (CA 27–29) is useful for monitoring patients with advanced stages of breast cancer. In early stages this test has low sensitivity and specificity. Because of this, The American Society of Clinical Oncology recommends using this test only during metastatic conditions. In most cases the CA 27-29 test does not provide sufficient information to consider treatment options. Major factors contributing to carcinoma of the breast are familial occurrence and hormonal level exposure, specifically estrogen. Other factors to the disease include the presence of fibrocystic disease with atypical hyperplasia, prior carcinoma of the uterus, and exposure to radiation of the chest. Several cancers can also raise the CA 27-29 levels such as cancer of the colon, stomach, kidney, lung, ovary, pancreas, uterus, and liver. First trimester pregnancy, endometriosis, ovarian cysts, benign breast disease, kidney disease, and liver disease are non-cancerous conditions that may yield an elevated CA 27-29.

Cancer antigen 15-3 (CA 15-3) is a normal product of breast cells. Overexpression of CA 15-3 is associated with metastatic breast cancer. This test is used to monitor breast cancer and to follow the course of treatment. Elevated serum CA 15-3 concentrations have been reported in 5% of stage I, 29% of stage II, 32% of stage III, and 95% of stage IV carcinoma of the breast. When used in conjunction with other clinical and diagnostic procedures, serial testing for CA 15-3 cancer antigen is useful for monitoring the course of disease and therapy in metastatic breast cancer patients, and for detection of recurrence in previously treated Stage II or Stage III breast cancer patients. In patients with known metastases, a reduction in CA 15-3 levels indicates a good response to treatment, while increasing levels indicate resistance to therapy and progressive disease. CA 15-3 is not sensitive or specific enough to be considered useful as a tool for cancer screening, but has been used as an approximation of the severity of the disease. Mild to moderate elevation of CA 15-3 is also seen in other conditions including liver and pancreatic cancer, cirrhosis, benign breast disorders, and infrequently in apparently healthy individuals, especially women who are pregnant or nursing. CA 15-3 elevations seen in non-cancerous conditions tend to be stable over time.

Cancer Antigen 125 (CA 125) is a cell surface protein often found on ovarian cancer cells and in some normal tissues. It is one of the protein antigens that has been associated with the presence of various cancers, but is most often positive in ovarian cancer. CA 125 concentrations may also be elevated in other types of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease. CA 125 is a useful tumor marker for evaluating therapy and monitoring disease status in ovarian cancer patients. As the levels decrease it is an indication that the therapy or treatment has been successful. Post-operatively, the CA 125 concentration correlates with tumor bulk and is a prognostic indicator of clinical outcome. It has been reported that patients with levels exceeding 35 U/mL have the highest risk for clinical recurrence. CA 125 is not useful as a screening mechanism because it is elevated in many non-cancerous conditions, although women who are at higher risk due to family history or other reasons are usually tested regularly as a precautionary method. When measured serially, serum CA 125 concentration typically corresponds with disease progression or regression. The rate of change in CA 125 is also highly prognostic. A rapid decrease in the level of CA 125 indicates a positive response to treatment. Elevated levels of CA 125 after the third course of primary chemotherapy are typically predictive of poor outcomes.

**Cancer Antigen 72-4:** Used to monitor therapy, detect recurrence of gastrointestinal cancer, and used to monitor ovarian cancer in conjunction with other cancer antigens. **Cancer Antigen 27-29:** Used to diagnose metastatic adenocarcinoma of the breast, monitor therapy and recurrence of breast carcinoma in patients in stages II and III. **Cancer Antigen 19-9:** Used to determine the differential diagnosis between pancreatic cancer and cancer of the bile ducts and non-cancerous conditions such as pancreatic. Also used to monitor management of pancreatic cancer. **Breast Cancer Antigen 15-3:** Used to determine the course of disease and therapy in metastatic breast cancer and management of stage II and II breast cancer. **Cancer Antigen 125:** Used to monitor and manage ovarian cancer and management of ovarian cancer with metastatic disease, disease progression, regression, and disease response to treatment.
**Cancer Antigen 72-4:** Increased in multiple tumor types and shows increasing levels with tumor progression and decreases with therapeutic response. **Cancer Antigen 27-29:** Increased in breast, colon, stomach, and kidney carcinoma, lung, ovarian, pancreatic, and liver cancer. Also increased during the first trimester of pregnancy, endometriosis, ovarian cysts, benign breast disease, and kidney disease. **Cancer Antigen 19-9:** Increased in pancreatic cancer, slightly elevated in colorectal, lung, and gallbladder cancer. Also slightly elevated with gallstones, pancreatitis, cystic fibrosis, and liver disease. **Breast Cancer Antigen 15-3:** Increased in metastatic breast cancer, slightly increased in pancreatic cancer, cirrhosis, benign breast disorders. **Cancer Antigen 125:** Increased in ovarian cancer, pelvic inflammatory disease, some other cancers, and during pregnancy and menstruation.

Cancer Antigen 72-4: 0-3.5 U/mL

CA 27-29: 0-35 U/mL

Cancer Antigen 19-9: <35 U/mL

Breast Cancer Antigen CA 15-3: 0 - 32.4 U/mL

Cancer Antigen 125: <30.2 U/mL

 

 

Enzyme Immunoassay, ELISA

Serum (SST) or Plasma

Stability

  • Ambient: 8 hours
  • Refrigerated: 1 week
  • Frozen: 1 year
Carcinoembryonic antigen (CEA), Alpha-fetoprotein (AFP), Human chorionic gonadotropin (hCG), Lactoferrin, EGFR, BRAF, KRAS muations analysis, Her2 by FISH, Microsatellite Instability, HE4.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login